Clinicopathological characteristics and outcome of high grade breast cancer: our 9 years’ experience

Introduction: The aim was to determine the characteristics of G3 breast cancers as well as to evaluate the treatment patients received and their outcome in terms of overall- and disease-free survival. Materials and Methods: 2,407 women affected by invasive breast cancer were retrospectively analyzed. Patients were divided into three groups according to the grading, to compare G3 cancers with G1 and G2 ones. Tumor, population characteristics, management, and outcomes were considered in the analysis. Results: The authors found that G3 breast cancers were associated with tumor characteristics indicative of more aggressive behavior and with reduced overall and disease-free survival. Although they were more frequently treated with demolitive surgery and chemotherapy, prognosis of G3 tumors at Stages I and II did not change in case of radical or conservative surgical treatment, while Stage III G3 tumors had a significant prognostic advantage by conservative surgery. Conclusions: G3 breast cancers should be considered with particular attention for their aggressiveness when planning the therapeutic procedure. However, breast demolitive surgery should be carefully scheduled and reserved to women who can not benefit from complementary therapies to conservative surgery.

reast neoplasms; Neoplasm grading; High grade breast cancer; Breast conservative surgery.

[1] Bertozzi S., Londero A.P., Cedolini C., Uzzau A., Seriau L., Bernardi S., et al.: “Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer”. Springerplus, 2015, 4, 688.

[2] Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Carbone A., Petri R., et al.: “Applicability of two different validated models to predict axillary non-sentinel lymph node status by sentinel node biopsy in a single Italian center”. Breast Cancer, 2015, 22, 350.

[3] Cedolini C., Bertozzi S., Londero A.P., Bernardi S., Seriau L., Concina S., et al.: “Type of breast cancer diagnosis, screening, and survival”. Clin. Breast Cancer, 2014, 14, 235.

[4] Bernardi S., Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Dri C., et al.: “Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases”. World J. Surg., 2012, 36, 714.

[5] Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., et al.: ‘Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999”. Arch. Pathol. Lab. Med., 2000, 124, 966.

[6] Elston C.W., Ellis I.O.: “Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up”. Histopathology, 1991, 19, 403.

[7] Gilchrist K.W., Kalish L., Gould V.E., Hirschl S., Imbriglia J.E., Levy W.M., et al.: “Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study”. Breast Cancer Res. Treat., 1985, 5, 3.

[8] Schumacher M., Schmoor C., Sauerbrei W., Schauer A., Ummenhofer L., Gatzemeier W., et al.: “The prognostic effect of histological tumor grade in node-negative breast cancer patients”. Breast Cancer Res. Treat., 1993, 25, 235.

[9] Dawson A.E., Austin R. Jr., Weinberg D.S.: “Nuclear grading of breast carcinoma by image analysis. Classification by multivariate and neural network analysis:”. Am. J. Clin. Pathol., 1991, 95, S29.

[10] Henson D.E., Ries L., Freedman L.S., Carriaga M.: “Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index”. Cancer, 1991, 68, 2142.

[11] Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F., Brunet M.: “Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas”. Cancer, 1989, 64, 1914.

[12] Contesso G., Mouriesse H., Friedman S., Genin J., Sarrazin D., Rouesse J.: “The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy”. J. Clin. Oncol., 1987, 5, 1378.

[13] Rank F., Dombernowsky P., Jespersen N.C., Pedersen B.V., Keiding N.: “Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial”. Cancer, 1987, 60, 1299.

[14] Davis B.W., Gelber R.D., Goldhirsch A., Hartmann W.H., Locher G.W., Reed R., et al.: “Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis”. Cancer, 1986, 58, 2662.

[15] Fisher E.R., Redmond C., Fisher B.: “Histologic grading of breast cancer”. Pathol. Annu., 1980, 15, 239.

[16] Arnone P., Zurrida S., Viale G., Dellapasqua S., Montagna E., Arnaboldi P., et al.: “The TNM classification of breast cancer: need for change”. Updates Surg., 2010, 62, 75.

[17] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Cattin F., et al.: “Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center”. Int. J. Clin. Exp. Pathol., 2014, 7, 364.

[18] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Moretti E., et al.: “Feasibility of concervative breast surgery and intraoperative radiation therapy for early breast cancer: A single-center, open, non-randomized, prospective pilot study”. Oncol. Rep., 2014, 31, 1539.

[19] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Giacomuzzi F., Carbone A.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases”. World J. Surg., 2012, 36, 1915.

[20] Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., et al.: “Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis”. Lancet, 2014, 384, 164.

[21] Haffty B.G., McCall L.M., Ballman K.V., McLaughlin S., Jagsi R., Ollila D.W., et al.: “Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int. J. Radiat. Oncol. Biol. Phys., 2016, 94, 493.

[22] Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., et al.: “Effect of preoperative chemotherapy on the outcome of women with operable breast cancer”. J. Clin. Oncol., 1998, 16, 2672.

[23] Woodward W.A., Strom E.A., Tucker S.L., Katz A., McNeese M.D., Perkins G.H., et al.: “Locoregional recurrence after doxorubicinbased chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 336.

[24] Cortazar P., Geyer C.E. Jr.: “Pathological complete response in neoadjuvant treatment of breast cancer”. Ann. Surg. Oncol., 2015, 22, 1441.

[25] Anderson S.J., Wapnir I., Dignam J.J., Fisher B., Mamounas E.P., Jeong J.H., et al.: “Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer”. J. Clin. Oncol., 2009, 27, 2466.

[26] Waeber M., Castiglione-Gertsch M., Dietrich D., Thürlimann B., Goldhirsch A., Brunner K.W., et al.: “Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation”. Ann. Oncol., 2003, 14, 1215.

[27] Salvadori B., Marubini E., Miceli R., Conti A.R., Cusumano F., Andreola S., et al.: “Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery”. Br. J. Surg., 1999, 86, 84.

[28] Osborne M.P., Borgen P.I., Wong G.Y., Rosen P.P., McCormick B.: “Salvage mastectomy for local and regional recurrence after breastconserving operation and radiation therapy”. Surg. Gynecol. Obstet., 1992, 174, 189.